VELCADE 3.5 mg powder for solution for injection clinical trials
7 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
This study looks at a new treatment, idecabtagene vicleucel (bb2121), for multiple myeloma that has come back or not responded to previous treatments. It compares this new treatment to standard options to see if it works better and is safe for patients aged 18 and over.
Germany · Spain · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
This study is looking at a new treatment combination for a type of blood cancer called multiple myeloma, for people who aren't having a stem cell transplant. It compares a new four-drug treatment with a standard three-drug treatment to see if the new one works better.
For: Multiple MyelomaSpain · Netherlands · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/3 Study of Ibrutinib in Combination With Rituximab Versus Physician’s Choice of Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab in Participants with Relapsed or Refractory Mantle Cell Lymphoma
This study looks at new treatments for a type of blood cancer called mantle cell lymphoma that has come back or hasn't responded to earlier treatments. We're comparing a drug named Ibrutinib with standard treatments like Lenalidomide or Bortezomib, all given with Rituximab, to see which works best.
For: Relapsed/Refractory Mantle Cell LymphomaCzechia · Spain · Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
This study is looking at a new way to treat AL amyloidosis, a rare condition where unhealthy proteins build up in your body. It compares a new drug called daratumumab with existing treatments to see if it works better and is safe for people newly diagnosed with the condition.
For: AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)Denmark · Italy · Netherlands - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma after a first-line therapy
This study compares a special stem cell treatment to standard care for people with multiple myeloma that has come back or worsened after their first treatment. It aims to see which approach helps people live longer and feel better over five years.
For: multiple myelomaGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in transplant-eligible patients with newly diagnosed multiple myeloma (GMMG HD8/ DSMM XIX)
This study looks at new ways to treat multiple myeloma, a type of blood cancer. It compares giving a new medicine called isatuximab in two different ways (through a drip or an injection) alongside standard treatments. The aim is to see if an injection works as well as a drip.
For: Multiple MyelomaAustria · Germany - AuthorisedTherapeutic confirmatory (Phase III)
An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma
This study is testing new treatments for a type of blood cancer called multiple myeloma that has come back or isn't responding to previous treatments. It compares new drugs, Linvoseltamab alone or with Carfilzomib, against standard treatments to see how well they work and if they are safe.
For: Relapsed Refractory Multiple MyelomaGreece · Spain · Poland